Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-31 pm EDT 5-day change 1st Jan Change
146.9 USD +1.09% Intraday chart for Johnson & Johnson -0.07% -6.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Higher Late Afternoon MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars MT
J&J: completes acquisition of Shockwave Medical CF
Johnson & Johnson Closes Acquisition of Shockwave Medical MT
Johnson & Johnson Completes Acquisition of Shockwave Medical MT
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers. CI
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400 MT
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM
J&J: encouraging results in the treatment of depression CF
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints MT
J&J's treatment for depression succeeds in late stage study RE
Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes CI
Sector Update: Health Care Stocks Fall Late Afternoon MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon MT
Sector Update: Health Care MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK MT
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion MT
J&J: acquisition of Swiss eczema biotech company CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal DJ
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
146.7 USD
Average target price
171.9 USD
Spread / Average Target
+17.23%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating